Sign up to access all valuation multiples
Deltex Medical Group PLC is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. The company has developed the gold standard for haemodynamic monitoring with oesophageal Doppler technology, which is marketed as TrueVue Doppler and often generically referred to by clinicians as ODM. The company's initial and principal technology is Doppler-based ultrasound oesophageal haemodynamic monitoring.
2000
37
Last FY Revenue $1.8M
Last FY EBITDA -$0.9M
$183M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Deltex Medical Group achieved revenue of $1.8M and an EBITDA of -$0.9M.
Deltex Medical Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Deltex Medical Group valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 63% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -52% | XXX | XXX | XXX |
| EBIT | XXX | -$0.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -48% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | XXX | -72% | XXX | XXX | XXX |
| Net Debt | XXX | $1.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Deltex Medical Group's stock price is $0.
Deltex Medical Group has current market cap of $181M, and EV of $183M.
See Deltex Medical Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $181M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Deltex Medical Group has market cap of $181M and EV of $183M.
Deltex Medical Group's trades at 102.9x EV/Revenue multiple, and -198.9x EV/EBITDA.
Equity research analysts estimate Deltex Medical Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Deltex Medical Group's P/E ratio is not available.
See valuation multiples for Deltex Medical Group and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $181M | XXX | $181M | XXX | XXX | XXX |
| EV (current) | $183M | XXX | $183M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 102.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -198.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -213.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -140.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -116.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDeltex Medical Group's revenue per employee in the last FY averaged $48K, while opex per employee averaged $0.1M for the same period.
Deltex Medical Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Deltex Medical Group's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Deltex Medical Group and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -52% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $48K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 112% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Deltex Medical Group acquired XXX companies to date.
Last acquisition by Deltex Medical Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Deltex Medical Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Deltex Medical Group founded? | Deltex Medical Group was founded in 2000. |
| Where is Deltex Medical Group headquartered? | Deltex Medical Group is headquartered in United States of America. |
| How many employees does Deltex Medical Group have? | As of today, Deltex Medical Group has 37 employees. |
| Who is the CEO of Deltex Medical Group? | Deltex Medical Group's CEO is Mr. Andrew Jonathan Mears. |
| Is Deltex Medical Group publicy listed? | Yes, Deltex Medical Group is a public company listed on PINX. |
| What is the stock symbol of Deltex Medical Group? | Deltex Medical Group trades under DTXMF ticker. |
| When did Deltex Medical Group go public? | Deltex Medical Group went public in 2009. |
| Who are competitors of Deltex Medical Group? | Similar companies to Deltex Medical Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Deltex Medical Group? | Deltex Medical Group's current market cap is $181M |
| Is Deltex Medical Group profitable? | Yes, Deltex Medical Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
